In research published in Developmental Medicine & Child Neurology, investigators developed a brief, reliable, and valid screening tool to help identify individuals with Duchenne muscular dystrophy (a ...

In research published in Developmental Medicine & Child Neurology, investigators have developed a brief, reliable, and valid ...

In research published in Developmental Medicine & Child Neurology , investigators developed a brief, reliable, and valid screening tool to help ...

This new program from Norton Hospital aims to bridge the gap between pediatric and adult care for those with ...

Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset muscular dystrophy, affecting about 1 in 8,000 people. While it is well known for causing muscle weakness and stiffness, DM1 also ...

Arrowhead Pharmaceuticals has surged over 240% in six months, driven by major partnerships and its RNAi drug pipeline. Recent catalysts include a $200M Novartis deal, $300M from Sarepta, and the first ...

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (SRPT). The milestone was ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead ...

The U.S. Food and Drug Administration is tightening restrictions on a gene therapy used to treat Duchenne muscular dystrophy after two teenagers died from liver failure linked to the medication. The ...

ELLSWORTH, Maine (WABI) - On Saturday, November 22, those who head to The Grand Theater in Ellsworth will get a chance to see the state of Maine in a way they’ve likely never seen before. “Seasons of ...